The prognostic impact of substantial lymphovascular space invasion in women with node negative FIGO stage I uterine carcinoma.

Autor: Bhatnagar AR; Department of Radiation Oncology, Henry Ford Health-Cancer, Detroit, MI 48202, USA., Ghanem AI; Department of Radiation Oncology, Henry Ford Health-Cancer, Detroit, MI 48202, USA; Clinical Oncology Department, University of Alexandria, Faculty of Medicine, Alexandria, Egypt., Alkamachi B; Department of Pathology and Laboratory Medicine, Henry Ford Health, Detroit, MI 48202, USA., Allo G; Department of Pathology and Laboratory Medicine, Henry Ford Health, Detroit, MI 48202, USA., Lin CH; Department of Public Health Sciences, Henry Ford Health, Detroit, MI 48202, USA., Hijaz M; Division of Gynecologic Oncology, Department of Women's Health Services, Henry Ford Health-Cancer, MI 48202, USA., Elshaikh MA; Department of Radiation Oncology, Henry Ford Health-Cancer, Detroit, MI 48202, USA. Electronic address: melshai1@hfhs.org.
Jazyk: angličtina
Zdroj: Gynecologic oncology [Gynecol Oncol] 2024 Sep; Vol. 188, pp. 44-51. Date of Electronic Publication: 2024 Jun 26.
DOI: 10.1016/j.ygyno.2024.06.009
Abstrakt: Objective: Substantial lymphovascular space invasion (LVSI) is an important predictor of lymph node (LN) involvement in women with endometrial carcinoma. We studied the prognostic significance of substantial LVSI in patients with 2009-FIGO stage-I uterine endometrioid adenocarcinoma (EC) who all had pathologic negative nodal evaluation (PNNE).
Methods: Pathologic specimens were retrieved and LVSI was quantified (focal or substantial) in women with stage-I EC who had a hysterectomy and PNNE. In addition to multivariate analysis (MVA), recurrence-free (RFS), disease-specific (DSS), and overall (OS) survival was compared between women with focal vs. substantial LVSI.
Results: 1052 patients were identified with a median follow-up of 9.7 years. 358 women (34%) received adjuvant radiotherapy. 907 patients (86.2%) had no LVSI, 87 (8.3%) had focal, and 58 (5.5%) had substantial LVSI. Five-year RFS was 93.3% (95% CI: 91.5-95.1), 76.8% (95% CI: 67.2-87.7) and 79.1% (95% CI: 67.6-95.3) for no, focal, and substantial LVSI(p < 0.0001). There was no statistically significant difference in 5-year RFS, DSS, OS, and in the patterns of initial recurrence between women with focal vs substantial LVSI. On MVA with propensity score matching, substantial LVSI was not independently associated with any survival endpoint compared to focal LVSI, albeit both were detrimental when compared to no LVSI. Age ≥ 60 years and higher grade were predictors of worse RFS, DSS, and OS. Additionally, comorbidity burden was an independent predictor for OS.
Conclusions: Our results suggest that substantial LVSI does not predict worse survival endpoints or different recurrence patterns in women with stage-I EC with PNNE when compared to focal LVSI.
Competing Interests: Declaration of competing interest All authors declare no conflicts of interest.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: